ABC transporters in breast cancer: their roles in multidrug resistance and beyond. (6th October 2022)

• Record Type: Journal Article
• Authors: Modi, Anupama; Roy, Dipayan; Sharma, Shailja; Vishnoi, Jeewan Ram; Pareek, Puneet; Elhence, Poonam; Sharma, Praveen; Purohit, Purvi
• Is Part Of: Journal of drug targeting. Volume 30:Number 9(2022)
• Page Start: 927
• Page End: 947
• Publication Date: 2022-10-06
• Subjects: ABC transporter -- breast cancer -- chemoresistance -- lncRNA -- miRNA -- polymorphism; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2022.2091578
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: ATP-binding cassette (ABC) transporters are membrane-spanning proteins involved in cholesterol homeostasis, transport of various molecules in and out of cells and organelles, oxidative stress, immune recognition, and drug efflux. They are long implicated in the development of multidrug resistance in cancer chemotherapy. Existing clinical and molecular evidence has also linked ABC transporters with cancer pathogenesis, prognostics, and therapy. In this review, we aim to provide a comprehensive update on all ABC transporters and their roles in drug resistance in breast cancer (BC). For solid tumours such as BC, various ABC transporters are highly expressed in less differentiated subtypes and metastases. ABCA1, ABCB1 and ABCG2 are key players in BC chemoresistance. Restraining these transporters has evolved as a possible mechanism to reverse this phenomenon. Further, ABCB1 and ABCC1 are important in BC prognosis. Newer therapeutic approaches have been developed to target all these molecules to dysregulate their effect, reduce cell viability, induce apoptosis, and increase drug sensitivity. In the future, targeted therapy for specific genetic variations and upstream or downstream molecules can help improve patient prognosis.